UnitedHealth reported solid renewal results driven by premium increases that have strengthened its membership base, lowered medical care costs, and improved profit margins in the first quarter of 2026. The company benefited from higher-than-expected payment increases for 2027 Medicare Advantage plans, which support its ongoing margin recovery over multiple years. Despite recent stock price gains and technical overbought signals causing some short-term valuation volatility, investors are advised to consider buying near $310-$320 for better safety and dividend yield potential. The long-term price target remains $428, reflecting confidence in sustained growth and profitability.
UnitedHealth Group reported a strong second-quarter net income of $5.48 billion, driven by a significant reduction in medical costs. The company lowered its medical care ratio to 86.7% from 89.4% year-over-year by exiting unprofitable markets and man...
UnitedHealth Group reported second-quarter earnings that surpassed expectations, driven by better management of high medical costs and AI investments to streamline operations. The company raised its 2026 adjusted earnings forecast to $19.50-$20 per s...
Piper Sandler raised its price target for UnitedHealth Group to $475, suggesting a 13.3% upside from its current price of $419.23. The company, the largest U.S. health insurer, has consistently beaten earnings estimates, with its latest EPS of $7.23 ...
The SCHD ETF has returned just under 2% in the past month, outperforming the S&P 500 ETF (SPY) by nearly 1%. Year-to-date, about 30 SCHD holdings have more than doubled the returns of SPY, which has returned 9.8%. Additionally, 31 SCHD holdings are t...
Elevance Health and UnitedHealth Group, two of the largest U.S. health insurers, are set to report their second-quarter earnings this week. Investors and analysts are watching closely to see if these companies have maintained control over rising medi...
